Follow
In my latest Clinical Pipeline column for Nature Medicine, a look at iPSC therapy for heart failure.
"Heartseed is not the only company currently performing clinical trials with iPSC-derived cardiomyocytes. Help Therapeutics in China is also using an approach with allogeneic iPSC-derived cardiomyocytes, and Göttingen University is running a trial for patients with end- stage heart failure using engineered heart muscle composed of a mixture of iPSC- derived cardiomyocytes and stromal cells."
